194 related articles for article (PubMed ID: 24678002)
1. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
[TBL] [Abstract][Full Text] [Related]
2. Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.
Ekerljung L; Wållberg H; Sohrabian A; Andersson K; Friedman M; Frejd FY; Ståhl S; Gedda L
Bioconjug Chem; 2012 Sep; 23(9):1802-11. PubMed ID: 22882002
[TBL] [Abstract][Full Text] [Related]
3. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
4. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
[TBL] [Abstract][Full Text] [Related]
5. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
6. A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3.
Rau A; Kocher K; Rommel M; Kühl L; Albrecht M; Gotthard H; Aschmoneit N; Noll B; Olayioye MA; Kontermann RE; Seifert O
MAbs; 2021; 13(1):1902034. PubMed ID: 33752566
[TBL] [Abstract][Full Text] [Related]
7. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
8. Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin.
Nilvebrant J; Åstrand M; Georgieva-Kotseva M; Björnmalm M; Löfblom J; Hober S
PLoS One; 2014; 9(8):e103094. PubMed ID: 25089830
[TBL] [Abstract][Full Text] [Related]
9. Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.
Malm M; Frejd FY; Ståhl S; Löfblom J
MAbs; 2016 Oct; 8(7):1195-1209. PubMed ID: 27532938
[TBL] [Abstract][Full Text] [Related]
10. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
Wållberg H; Löfdahl PK; Tschapalda K; Uhlén M; Tolmachev V; Nygren PK; Ståhl S
Protein Expr Purif; 2011 Mar; 76(1):127-35. PubMed ID: 21029777
[TBL] [Abstract][Full Text] [Related]
11. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
12. Cellular effects of HER3-specific affibody molecules.
Göstring L; Malm M; Höidén-Guthenberg I; Frejd FY; Ståhl S; Löfblom J; Gedda L
PLoS One; 2012; 7(6):e40023. PubMed ID: 22768204
[TBL] [Abstract][Full Text] [Related]
13. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
Malm M; Kronqvist N; Lindberg H; Gudmundsdotter L; Bass T; Frejd FY; Höidén-Guthenberg I; Varasteh Z; Orlova A; Tolmachev V; Ståhl S; Löfblom J
PLoS One; 2013; 8(5):e62791. PubMed ID: 23675426
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
Steffen AC; Wikman M; Tolmachev V; Adams GP; Nilsson FY; Ståhl S; Carlsson J
Cancer Biother Radiopharm; 2005 Jun; 20(3):239-48. PubMed ID: 15989469
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.
Fleetwood F; Klint S; Hanze M; Gunneriusson E; Frejd FY; Ståhl S; Löfblom J
Sci Rep; 2014 Dec; 4():7518. PubMed ID: 25515662
[TBL] [Abstract][Full Text] [Related]
18. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.
Mazor Y; Sachsenmeier KF; Yang C; Hansen A; Filderman J; Mulgrew K; Wu H; Dall'Acqua WF
Sci Rep; 2017 Jan; 7():40098. PubMed ID: 28067257
[TBL] [Abstract][Full Text] [Related]
19. Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
Orlova A; Magnusson M; Eriksson TL; Nilsson M; Larsson B; Höidén-Guthenberg I; Widström C; Carlsson J; Tolmachev V; Ståhl S; Nilsson FY
Cancer Res; 2006 Apr; 66(8):4339-48. PubMed ID: 16618759
[TBL] [Abstract][Full Text] [Related]
20. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
